Robert B Geller
Overview
Explore the profile of Robert B Geller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Humphreys S, Geller R, Walden P
Oncol Ther
. 2022 Sep;
10(2):351-361.
PMID: 36114331
Granulocyte colony-stimulating factor (G-CSF) biologics, such as pegfilgrastim, are a standard of care in supportive cancer treatment that are administered once per chemotherapy cycle to reduce the incidence of febrile...
2.
Finck B, Geller R, Walden P
Adv Ther
. 2021 Apr;
38(6):3483-3486.
PMID: 33914268
No abstract available.
3.
Schwartzberg L, Marks S, Gabrail N, Geller R, Kish J
J Comp Eff Res
. 2019 May;
8(9):657-670.
PMID: 31070042
To evaluate real-world effectiveness of guideline-recommended palonosetron-containing antiemetic regimens in patients receiving highly (HEC) or moderately emetogenic (MEC) chemotherapy. This retrospective analysis used records of adults receiving first-line chemotherapy and...
4.
Schwartzberg L, McLaughlin T, Geller R, Gabrail N, Marks S
J Comp Eff Res
. 2018 Oct;
7(12):1161-1170.
PMID: 30304955
Aim: Real-world palonosetron effectiveness was evaluated in an antiemetic regimen with highly emetogenic chemotherapy (HEC). Patients & Methods: In this Phase IV, prospective, multicenter observational study, HEC-treated cancer patients received...
5.
Boccia R, Geller R, Clendeninn N, Ottoboni T
Future Oncol
. 2018 Oct;
15(3):297-303.
PMID: 30301373
Aim: Fosaprepitant, an intravenous neurokinin-1 receptor antagonist for chemotherapy-induced nausea and vomiting, contains polysorbate 80, which is associated with infusion-site adverse events (ISAEs) and hypersensitivity systemic reactions (HSRs). This study...
6.
Schnadig I, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, et al.
Cancer Manag Res
. 2017 Jun;
9:179-187.
PMID: 28579832
Background: APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy...
7.
Lazarus H, Perez W, Klein J, Kollman C, Bate-Boyle B, Bredeson C, et al.
Br J Haematol
. 2006 Feb;
132(6):755-69.
PMID: 16487177
Most acute myeloid leukaemia (AML) patients lack human leucocyte antigen-identical sibling donors for transplantation. Autotransplants and unrelated donor (URD) transplants are therapeutic options. To compare autologous versus URD transplantation for...